A comparative study of the bioavailability of seven formulations of phenytoin was carried out on 17 patients with epilepsy who were taking phenytoin regularly as part of their drug therapy. Three patients withdrew for personal reasons. No significant differences were found between Epanutin capsules and other generic formulations. However significant differences were noted between the generic pr...

Anticonvulsants have long been recognized as a cause of hypersensitivity reactions. Phenytoin hypersensitivity can be traced to 1916, when phenylethylhydantoin (phenytoin sodium), which was used to treat children with Sydenham chorea, was found to induce a hypersensitivity reaction. Phenytoin was then known as a “nerve sedative,” and the hypersensitivity reaction, “nirvanol sickness,” resolved ...

Our objective was to investigate the relationship between phenytoin bioavailability, enteral feeding and serum albumin levels in patients admitted to neurology/neurosurgery ITU, via case studies of three patients. The research was performed at the Walton centre for Neurology and Neurosurgery NHS Trust, Liverpool, England, and our subjects consisted of three cases admitted to ITU (1 status epile...

A randomised, controlled, double-blind clinical trial designed to determine the effectiveness of phenytoin in preventing epilepsy in patients who had suffered a serious head injury is reported. One hundred and sixty-four patients were randomly assigned to treatment with phenytoin or placebo capsules for one year. Patients who had a fit within one week of injury were excluded. Drug levels were m...

Phenytoin (diphenlhydantion or Dilantin) is a highly effective and widely prescribed anticonvulsant agent and antiarrhythmic agent in the treatment of grand mal and psychomotor epilepsy. Phentoin was introduced into therapy in 1937 for effective convulsive disorder with a common side effect being gingival hyperplasia. In dermatology due to the stimulatory effect on the connective tissue it is u...

The influence of aging on the pharmacokinetics of phenytoin at steady-state was evaluated retrospectically by comparing apparent oral clearance values (CL/F) in 75 patients aged 65-90 years (mean, 71.7 +/- 5.3 years) receiving phenytoin alone (n = 58) or in combination with phenobarbital (n = 17) and in an equal number of control patients aged 20-50 years (mean, 36.7 +/- 8.5 years) matched for ...

ABSTRACT Background: Data on prescribing patterns of antiepileptic drugs (AEDs) to older adult inpatients are limited. Objective: To assess changes in AEDs with late-onset epilepsy between 2009-2010 and 2015-2019, interpret any unexpected over the 2015-2019 period. Methods: Patients aged ≥60 years from a tertiary center were selected. Demographic data, seizure characteristics etiology, comorbid...